Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart

Immunocore Holdings plc

2024-Q3 EPS reported -$0.55 revenue$226,150,000

KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.
GAAP EPS $0.17 (diluted), net income $8.7M vs $0.9M in Q3 2023; cash $901.3M at Sept 30, 2024.
CFO Brian Di Donato to leave end of 2024; search for replacement in progress.
Brenetafusp (PRAME-A02) Phase 1 data at ESMO; NSCLC signal-detection shift delays initial data release.
Plans to repay $50M loan by end of 2024; pay ~$40M in sales-related rebate accruals in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.